N-Terminal Pro-B-type Natriuretic Peptide Levels in the Korean General Population |
Lee, Kyung-Hoon
(Division of Cardiology, Gachon University of Medicine and Science, Gil Medical Center)
Kim, Jang-Young (Department of Cardiology, Wonju College of Medicine, Yonsei University) Koh, Sang-Baek (Department of Preventive Medicine,Wonju College of Medicine, Yonsei University) Lee, Seung-Hwan (Department of Cardiology, Wonju College of Medicine, Yonsei University) Yoon, Jung-Han (Department of Cardiology, Wonju College of Medicine, Yonsei University) Han, Sang-Woo (Department of Cardiology, Wonju College of Medicine, Yonsei University) Park, Jong-Ku (Department of Preventive Medicine,Wonju College of Medicine, Yonsei University) Choe, Kyung-Hoon (Department of Cardiology, Wonju College of Medicine, Yonsei University) Yoo, Byung-Su (Department of Cardiology, Wonju College of Medicine, Yonsei University) |
1 | Mueller T, Gegenhuber A, Dieplinger B, Poelz W, Haltmayer M. Longterm stability of endogenous B-type natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP) in frozen plasma samples. Clin Chem Lab Med 2004;42:942-4. |
2 | Bruch C, Fischer C, Sindermann J, Stypmann J, Breithardt G, Gradaus R. Comparison of the prognostic usefulness of N-terminal pro-brain natriuretic peptide in patients with heart failure with versus without chronic kidney disease. Am J Cardiol 2008;102:469-74. DOI ScienceOn |
3 | Wang HS, Yoo BS, Chung IY, et al. Is B-type natriuretic peptide (BNP) measurement useful test for diagnosing systolic heart failure in patients with moderate to severe renal insufficiency? Korean Circ J 2005;35: 897-903. DOI |
4 | Almirez R, Protter AA. Clearance of human brain natriuretic peptide in rabbits: effect of the kidney, the natriuretic peptide clearance receptor, and peptidase activity. J Pharmacol Exp Ther 1999;289:976-80. |
5 | Coste J, Jourdain P, Pouchot J. A gray zone assigned to inconclusive results of quantitative diagnostic tests: application to the use of brain natriuretic peptide for diagnosis of heart failure in acute dyspneic patients. Clin Chem 2006;52:2229-35. DOI ScienceOn |
6 | Ewald B, Ewald D, Thakkinstian A, Attia J. Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction. Intern Med J 2008;38:101-13. DOI ScienceOn |
7 | Austin MJ, Heneghan MA. Multiple biomarkers and cardiovascular risk. N Engl J Med 2008;359:760-1. DOI |
8 | Galasko GI, Lahiri A, Barnes SC, Collinson P, Senior R. What is the normal range for N-terminal pro-brain natriuretic peptide?: how well does this normal range screen for cardiovascular disease? Eur Heart J 2005;26:2269-76. DOI ScienceOn |
9 | Marz W, Tiran B, Seelhorst U, et al. N-terminal pro-B-type natriuretic peptide predicts total and cardiovascular mortality in individuals with or without stable coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health Study. Clin Chem 2007;53:1075-83. DOI ScienceOn |
10 | Magnusson M, Melander O, Israelsson B, Grubb A, Groop L, Jovinge S. Elevated plasma levels of Nt-proBNP in patients with type 2 diabetes without overt cardiovascular disease. Diabetes Care 2004;27:1929-35. DOI ScienceOn |
11 | Hildebrandt P, Richards AM. Amino-terminal pro-B-type natriuretic peptide testing in patients with diabetes mellitus and with systemic hypertension. Am J Cardiol 2008;101:21-4. |
12 | Wang TJ, Larson MG, Levy D, et al. Heritability and genetic linkage of plasma natriuretic peptide levels. Circulation 2003;108:13-6. DOI ScienceOn |
13 | Goetze JP, Mogelvang R, Maage L, et al. Plasma pro-B-type natriuretic peptide in the general population: screening for left ventricular hypertrophy and systolic dysfunction. Eur Heart J 2006;27:3004-10. DOI ScienceOn |
14 | Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002;40:976-82. DOI ScienceOn |
15 | Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004;109:594-600. DOI ScienceOn |
16 | Raymond I, Groenning BA, Hildebrandt PR, et al. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 2003;89:745-51. DOI |
17 | Segawa T, Nakamura M, Itai K, Onoda T, Okayama A, Hiramori K. Plasma B-type natriuretic peptide levels and risk factors for congestive heart failure in a Japanese general population. Int Heart J 2005;46: 465-75. DOI ScienceOn |
18 | Ordonez-Llanos J, Collinson PO, Christenson RH. Amino-terminal pro-B-type natriuretic peptide: analytic considerations. Am J Cardiol 2008;101:9-15. |
19 | Krauser DG, Chen AA, Tung R, Anwaruddin S, Baggish AL, Januzzi JL Jr. Neither race nor gender influences the usefulness of aminoterminal pro-brain natriuretic peptide testing in dyspneic subjects: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. J Card Fail 2006;12:452-7. DOI ScienceOn |
20 | Januzzi JL Jr, Chen-Tournoux AA, Moe G. Amino-terminal pro-Btype natriuretic peptide testing for the diagnosis or exclusion of heart failure in patients with acute symptoms. Am J Cardiol 2008;101:29-38. DOI ScienceOn |
21 | Kohno M, Horio T, Yokokawa K, et al. Brain natriuretic peptide as a cardiac hormone in essential hypertension. Am J Med 1992;92:29-34. DOI ScienceOn |
22 | Rossi A, Enriquez-Sarano M, Burnett JC Jr, Lerman A, Abel MD, Seward JB. Natriuretic peptide levels in atrial fibrillation: a prospective hormonal and Doppler-echocardiographic study. J Am Coll Cardiol 2000;35:1256-62. DOI |
23 | Choe HM, Yoo BS, Ryu HY, et al. The early changing pattern of the Btype natriuretic peptide concentration and its significance as a prognostic marker after acute myocardial infarction. Korean Circ J 2006;36: 526-34. DOI |
24 | Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350:655-63. DOI ScienceOn |
25 | Nakamura M, Endo H, Nasu M, Arakawa N, Segawa T, Hiramori K. Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population. Heart 2002;87:131-5. DOI |
26 | Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgentcare setting. J Am Coll Cardiol 2001;37:379-85. DOI ScienceOn |
27 | McDonagh TA, McDonald K, Maisel AS. Screening for asymptomatic left ventricular dysfunction using B-type natriuretic Peptide. Congest Heart Fail 2008;14(4 Suppl):5-8. DOI |
28 | Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997;96:509-16. DOI ScienceOn |
29 | Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997;350:1349-53. DOI ScienceOn |
30 | Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-7. DOI ScienceOn |
31 | Sutton TM, Stewart RA, Gerber IL, et al. Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation. J Am Coll Cardiol 2003;41:2280-7. DOI ScienceOn |
32 | Yoo BS, Kim WJ, Jung HS, et al. The clinical experiences of B-type natriuretic peptide blood concentrations for diagnosis in congestive heart failure: the single hospital experience based on the large clinical database. Korean Circ J 2004;34:684-92. DOI |